Genetic risk factors for inhibitors in haemophilia A

European Journal of Haematology

Volumn 94, Issue s77, 2015, Pages 7-10

  Bardi, Edit ^a   Astermark, Jan ^b  

^a KEPLER UNIVERSITY HOSPITAL   (Austria)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Ethnicity; Genetics; Haemophilia; HLA; Immune regulatory molecules; Inhibitors; Mutation

Indexed keywords

ANTIBODY; BLOOD CLOTTING FACTOR 8; CYTOKINE; HLA ANTIGEN CLASS 2;

ANTAGONISTS AND INHIBITORS; BLACK PERSON; BLOOD; CAUCASIAN; ETHNOLOGY; GENE EXPRESSION; GENETICS; GENOTYPE ENVIRONMENT INTERACTION; HEMOPHILIA A; HUMAN; IMMUNOLOGY; MUTATION; PROGNOSIS; RISK FACTOR; TREATMENT OUTCOME;

AFRICAN CONTINENTAL ANCESTRY GROUP; ANTIBODIES; CYTOKINES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FACTOR VIII; GENE EXPRESSION; GENE-ENVIRONMENT INTERACTION; HEMOPHILIA A; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; MUTATION; PROGNOSIS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84920267316     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12495     Document Type: Review

References (22)

1. Ehrenforth S, Kreuz W, Scharrer I, Linde R, Funk M, G€ung€or T, Krackhardt B, Kornhuber B. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992;339:594-8.
2. Pfistershammer K, St€ockl J, Siekmann J, Turecek PL, Schwarz HP, Reipert BM. Recombinant factor VIII and factor VIII-von Willebrand factor complex do not present danger signals for human dendritic cells. Thromb Haemost 2006; 96:309-16.
3. Oldenburg J, Brackmann HH, Schwaab R. Risk factors for inhibitor development in haemophilia A. Haematologica 2000;85(10 Suppl.):7-13.
4. Astermark J, Berntorp E, White GC, Kroner BL, MIBS Study Group. The Malm€o International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients. Haemophilia 2001; 7:267-72.
5. Klintman J, Hillarp A, Donfield S, Berntorp E, Astermark J. Antibody formation and specificity in Bethesda-negative brother pairs with haemophilia A. Haemophilia 2013;19:106-12.
6. Viel KR, Ameri A, Abshire TC, et al. Inhibitors of factor VIII in black patients with hemophilia. N Engl J Med 2009;360: 1618-27.
7. Schwarz J, Astermark J, Menius ED, et al.; Hemophilia Inhibitor Genetics Study Combined Cohort. F8 haplotype and inhibitor risk: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort. Haemophilia 2013;19:113-8.
8. Howard TE, Yanover C, Mahlangu J, Krause A, Viel KR, Kasper CK, Pratt KP. Haemophilia management: time to get personal? Haemophilia 2011;17:721-8.
9. Gouw SC, van den Berg HM, Oldenburg J, et al. F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis. Blood 2012;119:2922-34.
10. Pandey GS, Yanover C, Miller-Jenkins LM, Sauna ZE, et al.; PATH (Personalized Alternative Therapies for Hemophilia) Study Investigators. Endogenous factor VIII synthesis from the intron 22-inverted F8 locus may modulate the immunogenicity of replacement therapy for hemophilia A. Nat Med 2013;19:1318-24.
11. Hay CR, Ollier W, Pepper L, Cumming A, Keeney S, Goodeve AC, Colvin BT, Hill FG, Preston FE, Peake IR. HLA class II profile: a weak determinant of factor VIII inhibitor development in severe haemophilia A. UKHCDO Inhibitor Working Party. Thromb Haemost 1997;77:234-7.
12. Oldenburg J, Picard JK, Schwaab R, Brackmann HH, Tuddenham EG, Simpson E. HLA genotype of patients with severe haemophilia A due to intron 22 inversion with and without inhibitors of factor VIII. Thromb Haemost 1997; 77:238-42.
13. Pavlova A, Delev D, Lacroix-Desmazes S, Schwaab R, Mende M, Fimmers R, Astermark J, Oldenburg J. Impact of polymorphisms of the major histocompatibility complex class II, interleukin-10, tumor necrosis factor-alpha and cytotoxic T-lymphocyte antigen-4 genes on inhibitor development in severe hemophilia A. J Thromb Haemost 2009; 7:2006-15.
14. Pergantou H, Varela I, Moraloglou O, Economou M, Spanou K, Kapsimali Z, Constantinidou N, Platokouki H. Impact of HLA alleles and cytokine polymorphisms on inhibitors development in children with severe haemophilia A. Haemophilia 2013;19:706-10.
15. Astermark J, Oldenburg J, Pavlova A, Berntorp E, Lefvert AK; MIBS Study Group. Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A. Blood 2006;107: 3167-72.
16. Astermark J, Oldenburg J, Carlson J, et al. Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood 2006;108:3739-45.
17. Astermark J, Wang X, Oldenburg J, Berntorp E, Lefvert AK; MIBS Study Group. Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A. J Thromb Haemost 2007;5:263-5.
18. Lozier JN, Rosenberg PS, Goedert JJ, Menashe I. A casecontrol study reveals immunoregulatory gene haplotypes that influence inhibitor risk in severe haemophilia A. Haemophilia 2011;17:641-9.
19. Peng A, Straubinger RM, Balu-Iyer SV. Phosphatidylinositol containing lipidic particles reduces immunogenicity and catabolism of factor VIII in hemophilia a mice. AAPS J 2010;12: 473-81.
20. Gaitonde P, Peng A, Straubinger RM, Bankert RB, Balu-Iyer SV. Downregulation of CD40 signal and induction of TGF-b by phosphatidylinositol mediates reduction in immunogenicity against recombinant human factor VIII. J Pharm Sci 2012; 101:48-55.
21. Chaves D, Belisário A, Castro G, Santoro M, Rodrigues C. Analysis of cytokine genes polymorphism as markers for inhibitor development in haemophilia A. Int J Immunogenet 2010;37:79-82.
22. Astermark J, Donfield SM, Gomperts ED, et al.; Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort. The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort. Blood 2013;121:1446-54.